Evaluating OM-89 for reducing antibiotic use in urinary tract infections for patients with neurogenic bladder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial assesses the efficacy of OM-89, a non-antibiotic prophylactic treatment, compared to a placebo in patients with neurogenic bladder who frequently experience recurrent urinary tract infections (UTIs). The study focuses on individuals who have been using clean intermittent catheterization (CIC) and have a history of multiple antibiotic treatments for UTIs. By reducing antibiotic consumption, the trial aims to address the growing concern of multidrug-resistant bacteria and improve patient outcomes. Participants will be monitored for UTI recurrence and overall health improvements over the course of the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Person who has given written consent
* Patient aged 18 years or older
* Patient with a stabilised neurogenic bladder following spinal cord injury thaht has not progressed for more than 2 years and who has undergone a urodynamic examination in the last 2 years.
* Patients using CIC (5 to 6 per day)
* Patients who have received at least 6 courses of antibiotic treatment for UTIs in the 12 months prior to screening (whether for curative or prophylactic reasons)
* Patients with a negative urine culture between screening visit and randomisation or treated with antibiotics for urinary decontamination prior to randomisation.

Exclusion Criteria:

* Person who is not affiliated with the national health insurance system
* Person subject to a measure of legal protection (guardianship, tutorship)
* Person subject to a court order
* Adults unable to express consent
* Patients using a urinary drainage method other than CIC
* Patients with urinary lithiasis at the time of inclusion (assessed by renal imaging in the previous year as part of routine management for patients with a history(s) of lithiasis or within 3 years for patients with no history)
* Presence of an endo-urinary device (urinary prosthesis, ureteral stent)
* Enterocystoplasty or irradiated bladder (past or present)
* Known allergy or previous intolerance to the active substance or one of the excipients of OM-89 or placebo
* Patient requiring ongoing or short-term prolonged antibiotic therapy (e.g. infected bedsore, etc.)
* Patient treated with bacterial lysates (including OM-89) in the 6 months prior to randomisation
* Unable or unwilling to stop prophylactic antibiotic therapy prior to randomisation
* Patient with a known malignant tumour or neoplasia
* Patient with an autoimmune disease
* Patient treated with long-term or bolus corticosteroids, anti-CD20 and anti-rejection therapy in the 6 months prior to screening
* Patient currently taking part in another study on an investigational device or drug related to urinary tract infections, or who has received another investigational treatment in the 30 days prior to screening.
* Patient unable to collect information in a daily diary.
* Patient unable to understand follow-up by telephone.
* Patients planning to move to another residence in the year following randomisation
* Non-menopausal women who are not surgically sterile (bilateral oophorectomy or hysterectomy) AND pregnant, breast-feeding who are declare that they are planning to conceive at inclusion, or not using effective\* contraception.

Where it's running

• CHU Dijon Bourgogne
  Dijon, France Recruiting

Study contacts

• Study coordinator: Lionel PIROTH
• Email: lionel.piroth@chu-dijon.fr
• Phone: 0380293305

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigational Intermittent Catheter: First Look at Safety and Usability

  This study tests a new intermittent catheter in adult men who already self-catheterize to see if it is safe and easy to use compared with their current catheter.

  Recruiting Hollister Incorporated · Libertyville, Illinois · NCT07714694

• Patient and caregiver perspectives on bladder instillations for urinary symptoms

  This project talks with adults who have neurogenic bladder and their caregivers to see what they prefer and experience with bladder instillations of Lactobacillus, gentamicin, or both.

  Recruiting Medstar Health Research Institute · Washington D.C., District of Columbia · NCT07390591

• Intravesical Lactobacillus crispatus for urinary health in people with neurogenic bladder

  This study will test whether putting Lactobacillus crispatus into the bladder can help reduce urinary symptoms and urinary tract infections in adults with neurogenic lower urinary tract dysfunction who use intermittent catheters.

  Recruiting Early Phase 1 Medstar Health Research Institute · Washington D.C., District of Columbia · NCT07308808

• Improving pelvic rehabilitation after spinal cord injury with epidural stimulation

  This study is testing if using a special device to stimulate the spinal cord can help people with spinal cord injuries improve their bladder and bowel function through pelvic rehabilitation.

  Recruiting University College, London · Stanmore · NCT06515223

• Using Chlorhexidine Gluconate to improve outcomes for patients with chronic suprapubic catheters

  This study is testing if a special solution called Chlorhexidine can help people with chronic suprapubic catheters avoid urinary infections and improve their quality of life during catheter changes.

  Recruiting Yale University · New Haven, Connecticut · NCT06163469

• Modulating brain regions to treat bladder issues in multiple sclerosis

  This study is testing whether a new brain stimulation technique can help women with multiple sclerosis who have bladder problems feel better by focusing on the brain instead of just the bladder.

  Recruiting The Methodist Hospital Research Institute · Houston, Texas · NCT06072703

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.